• Home
  • Progression-free survival with fulvestrant 500 mg and alternative endocrine therapies as second-line treatment for advanced breast cancer: a network meta-analysis with parametric survival models.

Progression-free survival with fulvestrant 500 mg and alternative endocrine therapies as second-line treatment for advanced breast cancer: a network meta-analysis with parametric survival models.

Author List
Cope S, Ouwens MJ, Jansen JP, Schmid P
Publication
Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research
Publication ID (Profile URL)
https://researcherprofiles.org/profile/102292332
Publication Year
2013
PubMed ID
23538193
Publication Title
Cope S, Ouwens MJ, Jansen JP, Schmid P. Progression-free survival with fulvestrant 500 mg and alternative endocrine therapies as second-line treatment for advanced breast cancer: a network meta-analysis with parametric survival models. Value Health. 2013 Mar-Apr; 16(2):403-17.